Actively Recruiting
Imatinib TDM in GIST
Led by Reema A. Patel · Updated on 2026-02-17
28
Participants Needed
1
Research Sites
192 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Imatinib can lead to long recurrence free survival in patients diagnosed with gastrointestinal stromal tumors (GIST); however side effects can significantly hinder quality of life for our patients. This study will use therapeutic drug monitoring to improve quality of life and symptoms and assess how many patients maintain therapeutic levels. Free drug levels and pharmokinetics of imatinib will also be monitored.
CONDITIONS
Official Title
Imatinib TDM in GIST
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically or cytologically confirmed GIST with KIT mutation or PDGFRA mutation (non-D842V)
- Currently receiving imatinib initiated within the last 3 months or planned to start within the next 1 month
- Prior systemic chemotherapy for other malignancy allowed if completed within past 6 months with no evidence of disease
- Age 18 years or older
- ECOG performance status of 0 or 1
- Normal organ function
You will not qualify if you...
- Presence of PDGFRA D842V mutation
- Known allergy to imatinib or similar compounds
- Use of oral warfarin anticoagulation
- Use of strong inhibitors or inducers of CYP3A or CYP3A4, or drugs metabolized by CYP3A4 or CYP2D6
- Uncontrolled intercurrent illness
- Concurrent malignancy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Markey Cancer Center
Lexington, Kentucky, United States, 40536
Actively Recruiting
Research Team
Y
Yvonne A Taul, RN
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here